Exploring the association between metabolic syndrome, its components and subsequent cancer incidence: A cohort study in Catalonia.
cancer risk factors
epidemiology
metabolic studies
registries
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
02
05
2024
received:
12
02
2024
accepted:
07
06
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
ppublish
Résumé
Metabolic syndrome (MS) has emerged as a significant global health concern. The relationship between MS and the risk of cancer doesn't seem clear, whether examining by components or in combination. The objective of this study is to examine the relationship between MS, its components, and the overall risk of cancer, including the risk of 13 specific cancer types. We included 3,918,781 individuals aged 40 years or older sourced from the SIDIAP database between 2008 and 2017. Cox models were employed with MS components and their combinations. A subsample was created using a matched cohort (by age and sex). Incidence curves were computed to determine the time elapsed between the date of having 1-5 MS components and cancer incidence, compared to matched participants with no MS components, which showed that individuals who had one MS component experienced a greater incidence of cancer over 5 and 10 years than individuals with no MS, and the incidence rose with an increase in the number of MS components. Individuals exposed to MS components were diagnosed with cancer earlier than those who were not exposed to them. In the Cox model, HDL (HR 1.46, 95% CI: 1.41-1.52) and Glycemia (HR 1.40, 95% CI: 1.37-1.44) were the individual combinations with the highest risk of overall cancer. In combinations with two components, the highest HR was HDL+Glycemia (HR 1.52, 95% CI: 1.45-1.59) and Glycemia+HBP (HR 1.48, 95% CI: 1.45-1.50). In combinations with three components, the highest HR was HDL+Glycemia+HBP (HR 1.58, 95% CI: 1.55-1.62). In summary, having one or more MS components raises the risk of developing at least 11 cancer types and these risk differ according to type of component included. Some sex differences are also observed. Our findings suggest that implementing prevention measures aimed at specific MS components may lower the risk of various cancer types.
Sections du résumé
BACKGROUND
BACKGROUND
Metabolic syndrome (MS) has emerged as a significant global health concern. The relationship between MS and the risk of cancer doesn't seem clear, whether examining by components or in combination. The objective of this study is to examine the relationship between MS, its components, and the overall risk of cancer, including the risk of 13 specific cancer types.
METHODS
METHODS
We included 3,918,781 individuals aged 40 years or older sourced from the SIDIAP database between 2008 and 2017. Cox models were employed with MS components and their combinations. A subsample was created using a matched cohort (by age and sex). Incidence curves were computed to determine the time elapsed between the date of having 1-5 MS components and cancer incidence, compared to matched participants with no MS components, which showed that individuals who had one MS component experienced a greater incidence of cancer over 5 and 10 years than individuals with no MS, and the incidence rose with an increase in the number of MS components.
RESULTS
RESULTS
Individuals exposed to MS components were diagnosed with cancer earlier than those who were not exposed to them. In the Cox model, HDL (HR 1.46, 95% CI: 1.41-1.52) and Glycemia (HR 1.40, 95% CI: 1.37-1.44) were the individual combinations with the highest risk of overall cancer. In combinations with two components, the highest HR was HDL+Glycemia (HR 1.52, 95% CI: 1.45-1.59) and Glycemia+HBP (HR 1.48, 95% CI: 1.45-1.50). In combinations with three components, the highest HR was HDL+Glycemia+HBP (HR 1.58, 95% CI: 1.55-1.62).
CONCLUSION
CONCLUSIONS
In summary, having one or more MS components raises the risk of developing at least 11 cancer types and these risk differ according to type of component included. Some sex differences are also observed. Our findings suggest that implementing prevention measures aimed at specific MS components may lower the risk of various cancer types.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7400Subventions
Organisme : Instituto de Salud Carlos III
ID : PI17/00914
Organisme : Wereld Kanker Onderzoek Fonds
ID : 2017/1630
Informations de copyright
© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
Références
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640‐1645. doi:10.1161/CIRCULATIONAHA.109.192644
Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011–2016. JAMA. 2020;323:2526‐2528. doi:10.1001/jama.2020.4501
Scuteri A, Laurent S, Cucca F, et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015;22(4):486‐491. doi:10.1177/2047487314525529
Blanc‐Lapierre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent ME. Metabolic syndrome and prostate cancer risk in a population‐based case‐control study in Montreal, Canada. BMC Public Health. 2015;15:913. doi:10.1186/s12889-015-2260-x
López‐Jiménez T, Duarte‐Salles T, Plana‐Ripoll O, Recalde M, Xavier‐Cos F, Puente D. Association between metabolic syndrome and 13 types of cancer in Catalonia: a matched case‐control study. PLoS One. 2022;17:e0264634. doi:10.1371/journal.pone.0264634
Chen Y, Zhang L, Liu W, Wang K. Case‐control study of metabolic syndrome and ovarian cancer in Chinese population. Nutr Metab (Lond). 2017;14:21. doi:10.1186/s12986-017-0176-4
Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta‐analysis. Diabetes Care. 2012;35:2402‐2411. doi:10.2337/dc12-0336
Cirulli GO, Larcher A, Montorsi F, Martini A. Metabolic syndrome, obesity and cancer risk. In: Goonewardene SS, Brunckhorst O, Albala D, Ahmed K, eds. Men's Health and Wellbeing. Springer; 2022. doi:10.1007/978-3-030-84752-4_8
Bhaskaran K, Douglas I, Forbes H, dos‐Santos‐Silva I, Leon DA, Smeeth L. Body‐mass index and risk of 22 specific cancers: a population‐based cohort study of 5·24 million UK adults. Lancet. 2014;384:755‐765. doi:10.1016/S0140-6736(14)60892-8
Recalde M, Davila‐Batista V, Díaz Y, et al. Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. BMC Med. 2021;19:10. doi:10.1186/s12916-020-01877-3
Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes. 2008;32:304‐314. doi:10.1038/sj.ijo.0803713
Stocks T, Van Hemelrijck M, Manjer J, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. 2012;59:802‐810. doi:10.1161/HYPERTENSIONAHA.111.189258
Agnoli C, Grioni S, Sieri S, et al. Metabolic syndrome and breast cancer risk: a case‐cohort study nested in a multicentre italian cohort. PLoS One. 2015;10:e0128891. doi:10.1371/journal.pone.0128891
Arthur RS, Kabat GC, Kim MY, et al. Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study. Cancer Causes Control. 2019;30:355‐363. doi:10.1007/s10552-019-01139-5
World Health Organization. Overweight and obesity. 2021. Available from: http://www.who.int/news‐room/fact‐sheets/detail/obesity‐and‐overweight
Li L, Meng F, Xu D, Xu L, Qiu J, Shu X. Synergism between the metabolic syndrome components and cancer incidence: results from a prospective nested case‐control study based on the China Health and Retirement Longitudinal Study (CHARLS). BMJ Open. 2022;12:e061362. doi:10.1136/bmjopen-2022-061362
Li X, Chen H, Wang G, et al. Metabolic syndrome components and the risk of colorectal cancer: a population‐based prospective study in Chinese men. Front Oncol. 2019;9:1047. doi:10.3389/fonc.2019.01047
Oh TR, Han KD, Choi HS, et al. Metabolic syndrome resolved within two years is still a risk factor for kidney cancer. J Clin Med. 2019;8:1329. doi:10.3390/jcm8091329
Recalde M, Rodríguez C, Burn E, et al. Data resource profile: the information system for research in primary care (SIDIAP). Int J Epidemiol. 2022;51:e324‐e336. doi:10.1093/ije/dyac068
World Health Organization (WHO). Anatomical Therapeutic Chemical (ATC) Classification [Internet]. [cited 6 october 2023] https://www.who.int/tools/atc‐ddd‐toolkit/atc‐classification
Puente D, Lopez‐Jimenez T, Cos‐Claramunt X, Ortega Y, Duarte‐Salles T. Metabolic syndrome and risk of cancer: a study protocol of case‐control study using data from the information system for the development of research in primary care (SIDIAP) in Catalonia. BMJ Open. 2019;9:e025365. doi:10.1136/bmjopen-2018-025365
Recalde M, Manzano‐Salgado CB, Diaz Y, et al. Validation of cancer diagnoses in electronic health records: results from the information system for research in primary care (SIDIAP) in northeast Spain. Clin Epidemiol. 2019;11:1015‐1024. doi:10.2147/CLEP.S225568
Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. New advances on the functional cross‐talk between insulin‐like growth factor‐I and estrogen signaling in cancer. Cell Signal. 2012;24:1515‐1521. doi:10.1016/j.cellsig.2012.03.012
Clayton D, Hills M. Statistical Models in Epidemiology. Oxford University Press; 2013. doi:10.1002/sim.4780140113
Domínguez‐Berjón MF, Borrell C, Cano‐Serral G, et al. Construcción de un índice de privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA). Gac Sanit. 2008;22:179‐187. doi:10.1157/13123961
Buono G, Crispo A, Giuliano M, et al. Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. Breast Cancer Res Treat. 2020;182:401‐409. doi:10.1007/s10549-020-05701-7
Tan Y, Zhang X, Zhang W, et al. The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection in mainland China. Cancer Epidemiol Biomarkers Prev. 2019;28:2038‐2046. doi:10.1158/1055-9965.EPI-19-0303
Divella R, Gadaleta Caldarola G, Mazzocca A. Chronic inflammation in obesity and cancer cachexia. J Clin Med. 2022;11:2191. doi:10.3390/jcm11082191
Park JH, Han K, Hong JY, et al. Changes in metabolic syndrome status are associated with altered risk of pancreatic cancer: a Nationwide cohort study. Gastroenterology. 2022;162:509‐520.e7. doi:10.1053/j.gastro.2021.09.070
Mili N, Paschou SA, Goulis DG, Dimopoulos MA, Lambrinoudaki I, Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74:478‐497. doi:10.1007/s12020-021-02884-x
Miyashita Y, Hitsumoto T, Fukuda H, et al. Metabolic syndrome is linked to the incidence of pancreatic cancer. EClinicalMedicine. 2023;12(67):102353. doi:10.1016/j.eclinm.2023.102353
Park JH, Choi M, Kim JH, et al. Metabolic syndrome and the risk of thyroid cancer: a Nationwide population‐based cohort study. Thyroid. 2020;30:1496‐1504. doi:10.1089/thy.2019.0699
Sin S, Lee CH, Choi SM, Han KD, Lee J. Metabolic syndrome and risk of lung cancer: an analysis of Korean National Health Insurance Corporation Database. J Clin Endocrinol Metab. 2020;105:dgaa596. doi:10.1210/clinem/dgaa596
Gandaglia G, Leni R, Bray F, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4:877‐892. doi:10.1016/j.euo.2021.09.006
Yang X, Li X, Dong Y, et al. Effects of metabolic syndrome and its components on the prognosis of endometrial cancer. Front Endocrinol (Lausanne). 2021;12:780769. doi:10.3389/fendo.2021.780769
Xia B, He Q, Pan Y, et al. Metabolic syndrome and risk of pancreatic cancer: a population‐based prospective cohort study. Int J Cancer. 2020;147:3384‐3393. doi:10.1002/ijc.33172
Tran TT, Gunathilake M, Lee J, Kim J. Association between metabolic syndrome and its components and incident colorectal cancer in a prospective cohort study. Cancer. 2022;128:1230‐1241. doi:10.1002/cncr.34027
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 2019; 157:107843. doi:10.1016/j.diabres.2019.107843
Han F, Wu G, Zhang S, Zhang J, Zhao Y, Xu J. The association of metabolic syndrome and its components with the incidence and survival of colorectal cancer: a systematic review and meta‐analysis. Int J Biol Sci. 2021;17:487‐497. doi:10.7150/ijbs.52452
Lutz SZ, Hennenlotter J, Franko A, et al. Diabetes and the prostate: elevated fasting glucose, insulin resistance and higher levels of adrenal steroids in prostate cancer. J Clin Med. 2022;11:6762. doi:10.3390/jcm11226762
Johansen D, Stocks T, Jonsson H, et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the metabolic syndrome and cancer project. Cancer Epidemiol Biomarkers Prev. 2010;19:2307‐2317. doi:10.1158/1055-9965.EPI-10-0234
Almquist M, Johansen D, Björge T, et al. Metabolic factors and risk of thyroid cancer in the metabolic syndrome and cancer project (me‐can). Cancer Causes Control. 2011;22:743‐751. doi:10.1007/s10552-011-9747-2
Navarro‐Ledesma S, Hamed‐Hamed D, González‐Muñoz A, Pruimboom L. Physical activity, insulin resistance and cancer: a systematic review. Cancers (Basel). 2024;16:656. doi:10.3390/cancers16030656
Duvillier P. Hypertension artérielle et cancer: les liaisons dangereuses [Hypertension and cancer: Dangerous Liaisons]. Ann Cardiol Angeiol. 2022;71:317‐320. doi:10.1016/j.ancard.2022.08.003
Motterle G, DE Zorzi L, Zecchini G, et al. Metabolic syndrome and risk of prostate cancer: a systematic review and meta‐analysis. Panminerva Med. 2022;64:337‐343. doi:10.23736/S0031-0808.21.04507-9
Aune D, Sen A, Vatten LJ. Hypertension and the risk of endometrial cancer: a systematic review and meta‐analysis of case‐control and cohort studies. Sci Rep. 2017;7:44808. doi:10.1038/srep44808
Lim U, Gayles T, Katki HA, et al. Serum high‐density lipoprotein cholesterol and risk of non‐hodgkin lymphoma. Cancer Res. 2007;67:5569‐5574. doi:10.1158/0008-5472.CAN-07-0212
Wang H, Yan F, Cui Y, Chen F, Wang G, Cui W. Association between triglyceride glucose index and risk of cancer: a meta‐analysis. Front Endocrinol (Lausanne). 2023;12(13):1098492. doi:10.3389/fendo.2022.1098492
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433‐438. doi:10.1161/01.CIR.0000111245.75752.C6
Zhan ZQ, Chen YZ, Huang ZM, et al. Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta‐analysis of 31 prospective cohorts and mendelian randomization study. J Gastroenterol Hepatol. 2024;39:630‐641. doi:10.1111/jgh.16477